尿酸在非酒精性脂肪性肝病发生发展中的作用

李韶丰; 廖献花; 叶俊钊; 钟碧慧

doi:10.3969/j.issn.1001-5256.2016.09.041

尿酸在非酒精性脂肪性肝病发生发展中的作用

DOI: 10.3969/j.issn.1001-5256.2016.09.041

中山大学附属第一院消化科

详细信息

中图分类号: R575.5
计量
- 文章访问数: 2102
- HTML全文浏览量: 46
- PDF下载量: 501
- 被引次数: 0
出版历程
- 出版日期: 2016-09-20

Role of uric acid in the development and progression of nonalcoholic fatty liver disease

Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-sen University

摘要

摘要: 尿酸代谢异常与非酒精性脂肪性肝病(NAFLD)的发生发展密切相关。简述了尿酸与NAFLD的患病率和严重程度的关系,以及尿酸代谢紊乱可能通过胰岛素抵抗、氧化应激、直接影响脂肪合成代谢酶的表达及炎症反应等错综复杂的途径影响NAFLD发生发展的作用机制。指出控制尿酸有望成为NAFLD综合治疗手段之一。
- 脂肪肝 /
- 尿酸 /
- 综述
Abstract: Abnormal uric acid metabolism is closely associated with the development and progression of nonalcoholic fatty liver disease( NAFLD). This article describes the relationship between uric acid and the prevalence and severity of NAFLD,and point out that uric acid metabolic disorders directly affect the development and progression of NAFLD through complicated pathways such as insulin resistance,oxidative stress,direct influence on the expression of lipid synthetase,and inflammatory response. Control of uric acid is expected to become one of the multimodality therapies for NAFLD.
- fatty liver /
- uric acid /
- review

HTML全文

参考文献(39)

[1]Group of Fatty Liver and Alcoholic Liver Diseases,Society of Hepatology,Chinese Medical Association.Guidelines for management of non-alcoholic fatty liver disease[J].J Clin Hepatol,2010,26(2):120-124.(in Chinese)中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].临床肝胆病杂志,2010,26(2):120-124.

[2]LIAO XH,CAO X,LIU J,et al.Prevalence and features of fatty liver detected by physical examination in Guangzhou[J].World J Gastroenterol,2013,19(32):5334-5339.

[3]MARCHESINI G,BUGIANESI E,FORLANI G,et al.Nonalcoholic fatty liver,steatohepatitis,and the metabolic syndrome[J].Hepatology,2003,37(4):917-923.

[4]DU H,CHEN SL,WANG Y,et al.The epidemiology of hyperuricemia and gout in a community population of huangpu district in shanghai[J].Chin J Rheumatol,1998(2):16-19.(in Chinese)杜蕙,陈顺乐,王元,等.上海市黄浦区社区高尿酸血症与痛风流行病学调查[J].中华风湿病学杂志,1998(2):16-19.

[5]SHAO JH,MO BQ,YU RB,et al.Epidemiological study on hyperuricemia and gout in community of Nanjing[J].Chin J Dis Control Prev,2003,7(4):305-308.(in Chinese)邵继红,莫宝庆,喻荣彬,等.南京市社区人群高尿酸血症与痛风的流行病学调查[J].疾病控制杂志,2003,7(4):305-308.

[6]GU P.The incidence of hyperuricemia in 26 621 health checkup persons in Guangzhou city and analysis of associated diseases[J].Chin Trop Med,2006,6(6):1082-1084.(in Chinese)古萍.广州市体检人群高尿酸血症患病情况及相关疾病分析[J].中国热带医学,2006,6(6):1082-1084.

[7]PETTA S,CAMMA C,CABIBI D,et al.Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease[J].Aliment Pharmacol Ther,2011,34(7):757-766.

[8]HWANG IC,SUH SY,SUH AR,et al.The relationship between normal serum uric acid and nonalcoholic fatty liver disease[J].J Korean Med Sci,2011,26(3):386-391.

[9]ONAT A,UYAREL H,HERGENC G,et al.Serum uric acid is a determinant of metabolic syndrome in a population-based study[J].Am J Hypertens,2006,19(10):1055-1062.

[10]Chinese Society of Endocrinology,Chinese Medical Association.Chinese expert consensus on the treatment of hyperuricemia and gout[J].Chin J Endocrinol Metab,2013,29(11):913-920.(in Chinese)中华医学会内分泌学分会.高尿酸血症和痛风治疗的中国专家共识[J].中华内分泌代谢杂志,2013,29(11):913-920.

[11]WANG T,BI Y,XU M,et al.Serum uric acid associates with the incidence of type 2 diabetes in a prospective cohort of middle-aged and elderly Chinese[J].Endocrine,2011,40(1):109-116.

[12]KANSUI Y,OHTSUBO T,GOTO K,et al.Association of serum uric acid with blood pressure in Japanese men.Cross-sectional study in work-site group[J].Circ J,2011,75(12):2827-2832.

[13]CHEN JH,CHUANG SY,CHEN HJ,et al.Serum uric acid level as an independent risk factor for all-cause,cardiovascular,and ischemic stroke mortality:a Chinese cohort study[J].Arthritis Rheum,2009,61(2):225-232.

[14]NAKAGAWA T,KANG DH,FEIG D,et al.Unearthing uric acid:an ancient factor with recently found significance in renal and cardiovascular disease[J].Kidney Int,2006,69(10):1722-1725.

[15]ZHANG XJ.Pathogenesis and typing diagnosis of hyperuricemia[J].Chin J Cardiovase Med,2010,15(6):418-420.(in Chinese)张新军.高尿酸血症的发病机制与分型诊断[J].中国心血管杂志,2010,15(6):418-420.

[16]LI Y,XU C,YU C,et al.Association of serum uric acid level with non-alcoholic fatty liver disease:a cross-sectional study[J].J Hepatol,2009,50(5):1029-1034.

[17]XU CF,YU CH,XU L,et al.High serum uric acid increases the risk for nonalcoholic Fatty liver disease:a prospective observational study[J].PLo S One,2010,5(7):e11578.

[18]LEE JW,CHO YK,RYAN M,et al.Serum uric acid as a predictor for the development of nonalcoholic Fatty liver disease in apparently healthy subjects:a 5-year retrospective cohort study[J].Gut Liver,2010,4(3):378-383.

[19]SIROTA JC,MCFANN K,TARGHER G,et al.Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States:liver ultrasound data from the National Health and Nutrition Examination Survey[J].Metabolism,2013,62(3):392-399.

[20]SERTOGLU E,ERCIN CN,CELEBI G,et al.The relationship of serum uric acid with non-alcoholic fatty liver disease[J].Clin Biochem,2014,47(6):383-388.

[21]XU C,WAN X,XU L,et al.Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia:one stone hits two birds[J].J Hepatol,2015,62(6):1412-1419.

[22]EVANS JL,MADDUX BA,GOLDFINE ID.The molecular basis for oxidative stress-induced insulin resistance[J].Antioxid Redox Signal,2005,7(7-8):1040-1052.

[23]PESSIN JE,SALTIEL AR.Signaling pathways in insulin action:molecular targets of insulin resistance[J].J Clin Invest,2000,106(2):165-169.

[24]ZHU Y,HU Y,HUANG T,et al.High uric acid directly inhibits insulin signalling and induces insulin resistance[J].Biochem Biophys Res Commun,2014,447(4):707-714.

[25]AMES BN,CATHCART R,SCHWIERS E,et al.Uric acid provides an antioxidant defense in humans against oxidant-and radicalcaused aging and cancer:a hypothesis[J].Proc Natl Acad Sci U S A,1981,78(11):6858-6862.

[26]BAGNATI M,PERUGINI C,CAU C,et al.When and why a water-soluble antioxidant becomes pro-oxidant during copper-induced low-density lipoprotein oxidation:a study using uric acid[J].Biochem J,1999,340(Pt1):143-152.

[27]SAUTIN YY,NAKAGAWA T,ZHARIKOV S,et al.Adverse effects of the classic antioxidant uric acid in adipocytes:NADPH oxidase-mediated oxidative/nitrosative stress[J].Am J Physiol Cell Physiol,2007,293(2):c584-c596.

[28]LANASPA MA,SANCHEZ-LOZADA LG,CHOI YJ,et al.Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress:potential role in fructose-dependent and-independent fatty liver[J].J Biol Chem,2012,287(48):40732-40744.

[29]CHOI YJ,SHIN HS,CHOI HS,et al.Uric acid induces fat accumulation via generation of endoplasmic reticulum stress and SREBP-1c activation in hepatocytes[J].Lab Invest,2014,94(10):1114-1125.

[30]LEEMANS JC,CASSEL SL,SUTTERWALA FS.Sensing damage by the NLRP3 inflammasome[J].Immunol Rev,2011,243(1):152-62.

[31]WANG YG,FANG WL,WEI J,et al.The involvement of NLRX1 and NLRP3 in the development of nonalcoholic steatohepatitis in mice[J].J Chin Med Assoc,2013,76(12):686-692.

[32]MARTINON F,PETRILLI V,MAYOR A,et al.Gout-associated uric acid crystals activate the NALP3 inflammasome[J].Nature,2006,440(7081):237-441.

[33]TSCHOPP J,SCHRODER K.NLRP3 inflammasome activation:the convergence of multiple signalling pathways on ROS production?[J].Nat Rev Immunol,2010,10(3):210-215.

[34]ZHOU R,YAZDI AS,MENU P,et al.A role for mitochondria in NLRP3 inflammasome activation[J].Nature,2011,469(7329):221-225.

[35]XU X,SO JS,PARK JG,et al.Transcriptional control of hepatic lipid metabolism by SREBP and ChREBP[J].Semin Liver Dis,2013,33(4):301-311.

[36]LANASPA MA,CICERCHI C,GARCIA G,et al.Counteracting roles of AMP deaminase and AMP kinase in the development of fatty liver[J].PLo S One,2012,7(11):e48801.

[37]CICERCHI C,LI N,KRATZER J,et al.Uric acid-dependent inhibition of AMP kinase induces hepatic glucose production in diabetes and starvation:evolutionary implications of the uricase loss in hominids[J].Faseb J,2014,28(8):3339-3350.

[38]JUNG EJ,KWON SW,JUNG BH,et al.Role of the AMPK/SREBP-1 pathway in the development of orotic acid-induced fatty liver[J].J Lipid Res,2011,52(9):1617-1625.

[39]NAKATSU Y,SENO Y,KUSHIYAMA A,et al.The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model[J].Am J Physiol Gastrointest Liver Physiol,2015,309(1):g42-g51.

施引文献

资源附件(0)

访问统计